Webcast Schedules, Clinical Study Results, Stock Price Movements, and Grants - Analyst Notes on Illumina, Questcor, Quest Diagnostics, Raytheon and Lockheed Martin

NEW YORK, May 12, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Illumina Inc. (NASDAQ: ILMN), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Quest Diagnostics Inc. (NYSE: DGX), Raytheon Co. (NYSE: RTN) and Lockheed Martin Corporation (NYSE: LMT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2321-100free.

--
Illumina Inc. Analyst Notes
On May 5, 2014, Illumina, Inc. (Illumina) announced the webcast schedules for the Company's presentation at three upcoming investment conferences, namely: Bank of America Merrill Lynch Health Care Conference in Las Vegas, Nevada, on May 13, 2014 at 9:20 AM PT; Bank of America Merrill Lynch Global Technology Conference in San Francisco, California, on June 3, 2014 at 4:20 PM PT, and the Goldman Sachs Global Healthcare Conference in Rancho Palos Verdes, California, on June 11, 2014 at 9:20 AM PT. The full analyst notes on Illumina are available to download free of charge at:

http://www.analystsreview.com/2321-ILMN-12May2014.pdf

--
Questcor Pharmaceuticals, Inc. Analyst Notes
On May 5, 2014, Questcor Pharmaceuticals, Inc. (Questcor) announced that results from the first modern clinical study examining the use of H.P. Acthar® Gel (repository corticotropin injection) in systemic lupus erythematosus (SLE) has been published in the journal LUPUS. The Study evaluated the efficacy of Acthar in reducing SLE disease activity among patients who presented with moderately to severely active disease, in spite of receiving traditional SLE maintenance treatments. According to the Company, clinical trial results indicate Acthar may significantly reduce disease activity in patients with SLE. Acthar is approved by the U.S. Food and Drug Administration for 19 symptoms such as using during an exacerbation or as maintenance therapy in selected cases of SLE. The full analyst notes on Questcor are available to download free of charge at:

http://www.analystsreview.com/2321-QCOR-12May2014.pdf

--
Quest Diagnostics Inc. Analyst Notes
On May 7, 2014, Quest Diagnostics Inc. (Quest Diagnostics) stock closed at $55.90, up 0.6%, and in line with the broader market index NYSE Composite, which closed at $10.626.84, also up 0.6%. The Company's shares traded upwards for the second consecutive session. Quest Diagnostic's stock opened at $55.89 and oscillated between $55.56 and $56.20, during the day. A total of 3.34 million shares changed hands during the session, which was more than the previous day trading volume of 1.27 million shares and the 30-day average trading volume of 2.55 million shares. Quest Diagnostics will hold its Annual Shareholder Meeting on May 21, 2014 at 10:30 AM EDT The full analyst notes on Quest Diagnostics are available to download free of charge at:

http://www.analystsreview.com/2321-DGX-12May2014.pdf

--
Raytheon Co. Analyst Notes
On May 7, 2014, Raytheon Company (Raytheon) awarded $300,000 in scholarships and grants to middle school students and their schools as part of its MathMovesU program. According to the Company, MathMovesU program is an initiative aimed to engage middle school students in mathematics and science. Raytheon informed that each of the 150 middle school students from across the U.S. will receive a $1,000 MathMovesU Middle School Scholarship, which has to be used for a math, science or technology teaching program, or saved for college first year. Moreover, the Company stated that each recipient's school will receive a similar monetary grant from Raytheon. Pamela Erickson, Vice President of Corporate Affairs, Raytheon, said, "Encouraging middle school students to study math and science is important to ensuring they continue on to pursue a career in science, technology, engineering or math." The full analyst notes on Raytheon are available to download free of charge at:

http://www.analystsreview.com/2321-RTN-12May2014.pdf

--
Lockheed Martin Corporation Analyst Notes
On May 7, 2014, Lockheed Martin Corporation (Lockheed Martin) announced that it has successfully completed the first flight of the inaugural F-16 Fighting Falcon for the Iraq Air Force. As per the Company, the jet is the first of 36 F-16 Block 52 aircraft on order through the U.S. Department of Defense for Iraq. Lockheed Martin stated that the Foreign Military Sale to Iraq enhances the F-16's position as the world's most versatile and affordable 4th generation multi-role fighter with excess of 4,540 F-16s deliveries, till date. Lockheed Martin added that its F-16 production line is anticipated to continue through 2017, with major upgrades being lined up for all F-16 versions. The full analyst notes on Lockheed Martin are available to download free of charge at:

http://www.analystsreview.com/2321-LMT-12May2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review